Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Obtains CE Mark for PIK3CA Mutation Assay

NEW YORK – Qiagen said on Monday that it has obtained CE marking for its Therascreen PIK3CA RGQ PCR kit to aid in identifying breast cancer patients with a PIK3CA mutation.

As such, the test is now commercially available in Europe. The real-time qualitative PCR assay is performed on Qiagen's Rotor-Gene Q MDx instrument and uses the company's QIAamp in vitro diagnostic DNA sample prep kits for formalin-fixed paraffin-embedded tissue and plasma.

The assay detects 11 clinically actionably PIK3CA mutations, which are estimated to be present in about 40 percent of hormone receptor-positive, HER2-negative advanced breast cancer cases. Qiagen has a worldwide co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on detection of mutations in PIK3CA.

Qiagen codeveloped the test in collaboration with Novartis in the US as a companion diagnostic for alpelisib (Piqray). The assay received US Food and Drug Administration approval for this use in May.

"We are convinced that our Therascreen PIK3CA Kit … will provide a valuable testing option for those seeking new ways to combat advanced breast cancer," Jonathan Arnold, vice president and head of oncology and precision diagnostics at Qiagen, said in a statement.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.